Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

275
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
275
Obedience01:08

Obedience

35.7K
According to obedience research, we may harm others under the forceful pressures of an authority figure (Milgram, 1974). How about if the inappropriate orders were delivered with less force? The increasing interdependence between nurses and physicians compelled Hofling and his colleagues to explore nurses’ reactions to a potentially harmful medical request made by the perceived authority figure, the doctor (Hofling, Brotzman, Dalrymple, Graves, & Pierce, 1966). In this situation,...
35.7K
Ethics in Research01:56

Ethics in Research

25.8K
Today, scientists agree that good research is ethical in nature and is guided by a basic respect for human dignity and safety. However, this has not always been the case. Modern researchers must demonstrate that the research they perform is ethically sound.
25.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Deuruxolitinib: New Approval.

Clinical drug investigation·2026
Same author

Remibrutinib: First Approval.

Drugs·2026
Same author

Correction: Ifupinostat: First Approval.

Drugs·2026
Same author

Ifupinostat: First Approval.

Drugs·2025
Same author

Fosrolapitant/Palonosetron: First Approval.

Drugs·2025
Same author

Nipocalimab: First Approval.

Drugs·2025
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
查看所有相关文章

相关实验视频

Updated: Feb 13, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
05:05

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Published on: November 4, 2011

21.7K

贝维菲巴提德:首次获得批准

Simon Fung1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|February 12, 2026
PubMed
概括
此摘要是机器生成的。

贝维菲巴提德是一种糖蛋白IIb/IIIa对抗剂,现在已在中国批准用于经过皮肤冠状动脉干预的急性冠状动脉综合征患者. 这种治疗旨在减少诸如支架血栓形成和血流减缓等风险.

更多相关视频

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.6K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.6K

相关实验视频

Last Updated: Feb 13, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
05:05

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Published on: November 4, 2011

21.7K
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.6K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.6K

科学领域:

  • 心血管药理学心血管药理学
  • 整合素受体对抗性 整合素受体对抗性

背景情况:

  • 贝维菲巴提德是一种循环七环抗体,向糖蛋白IIb/IIIa和αvβ3整合素受体.
  • 它是由Bio-Thera Solutions开发的,用于治疗急性冠状动脉综合征 (ACS).

研究的目的:

  • 总结贝维菲巴提德的开发里程碑,导致其获得监管批准.
  • 突出贝维菲巴提德在通过皮肤冠状动脉干预 (PCI) 后减少并发症方面的作用.

主要方法:

  • 审查贝维菲巴提德的发展途径.
  • 分析其作为GP IIb/IIIa抗剂的作用机制.

主要成果:

  • 贝维菲巴提德于2024年6月25日在中国获得批准.
  • 已批准用于需要PCI的ACS患者,以减轻急性闭塞,支架血栓形成,没有再流和血流缓慢等风险.
  • 第一次批准是作为PCI,抗血小板和抗凝固剂治疗的辅助疗法.

结论:

  • 贝维菲巴提德的批准标志着ACS治疗的重大进展.
  • 它提供了一个新的治疗选择,以改善接受PCI的患者的治疗结果.
  • 降低血栓并发症的药物的有效性是关键的好处.